Avantax Advisory Services Inc. lowered its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 23.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,336 shares of the medical research company's stock after selling 1,365 shares during the quarter. Avantax Advisory Services Inc.'s holdings in Bio-Rad Laboratories were worth $1,424,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also added to or reduced their stakes in the company. Venturi Wealth Management LLC boosted its stake in Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after purchasing an additional 87 shares during the period. Asset Planning Inc bought a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at about $33,000. UMB Bank n.a. boosted its position in shares of Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after acquiring an additional 32 shares during the last quarter. Cape Investment Advisory Inc. bought a new stake in shares of Bio-Rad Laboratories during the 4th quarter valued at about $38,000. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Bio-Rad Laboratories during the 3rd quarter valued at about $55,000. Institutional investors own 65.24% of the company's stock.
Bio-Rad Laboratories Price Performance
Shares of NYSE BIO traded up $1.95 during trading hours on Friday, reaching $256.42. 1,439,995 shares of the stock traded hands, compared to its average volume of 289,974. The company has a market capitalization of $7.18 billion, a P/E ratio of -3.94 and a beta of 0.98. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 52-week low of $244.00 and a 52-week high of $387.99. The company's 50-day simple moving average is $303.23 and its two-hundred day simple moving average is $325.34.
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.
Wall Street Analysts Forecast Growth
BIO has been the subject of a number of research analyst reports. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Wells Fargo & Company dropped their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $395.20.
Check Out Our Latest Analysis on BIO
Bio-Rad Laboratories Company Profile
(
Free Report)
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Featured Stories
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
